Dana-Farber Cancer Institute boasts an impressive history of key discoveries about the immune system. Their powerhouse investigators have been on the frontlines. Dana-Farber’s research revealed that a protein known as PD-L1 is expressed on normal and cancer cells, enabling cancers to evade the immune response, and that blocking PD-L1 and a related protein, PD-1, could unleash the immune attack on tumor cells. PICI scientists at Dana-Farber are leaders in immunology and contribute greatly to our research agenda. Laurie H. Glimcher, MD | Director All Investigators Related Press Release PICI, JDRF and Helmsley Trust Form Research Initiative Cancer Research Heroes, Research Update Personalized Cancer Vaccines to Conquer Cancer Research Update Personalized cancer neoantigen vaccines show success in two small studies Announcement, Press Release First Patients Dosed in Pancreatic Platform Trial Partner Highlight Connecting Patients with Innovative Immunotherapies Our Impact, Partner Highlight All the Right Ingredients: The Founders of ArsenalBio Partner Highlight, Press Release NanoString and PICI Partner to Optimize Cell Therapies Announcement, Research Update Five Key Takeaways from ASCO 2021 Cancer Research Heroes, Patient Story When Cancer Becomes A Calling: Lacey Kitch